Belgium’s Ajinomoto doubles Indian small-molecule manufacturing cap with new facility

By | August 13, 2020

Belgian CDMO Ajinomoto Bio-Pharma Services has been on a run in recent of years expanding its operations around the world. That was the goal of an Indian joint venture buyout back in 2018—and now Ajinomoto is ready to double down on that earlier investment. 

Ajinomoto is building a 91,500-square-foot small molecule manufacturing facility at its existing Visakhapatnam, India, complex that will double the site’s production capacity, the Belgian CDMO said Thursday. 

The small-molecule facility began construction in late July and is expected to go online in 2022, Ajinomoto said. 

Sept. 15-17,2020

Cytiva Virtual Event: Tapas & Tech Talks Copy – Strategies for robust and scalable

Strategies for robust and scalable processes: from research through late-stage trials
(with Cytiva and IQVIA)

The CDMO’s newest facility will help produce active pharmaceutical ingredients (API) and drug intermediates with a total of 310,000 liters of capacity. In addition, Ajinomoto has renovated its existing laboratory space to boost its R&D efforts. 

All told, the expansion and renovations are expected to add 60 new jobs at the facility, Ajinomoto said. 

“The increased manufacturing capacity at Aji Bio-Pharma India offers a significant advantage for our small molecule customers, who now have a variety of options to meet their manufacturing needs,” said Peter Stuyck, vice president and head of European operations.

RELATED: Ajinomoto Bio-Pharma buys Indian API plant from JV partner

Read more on

FiercePharma: Pharma